The Oncology CRO
for Biotech, Powered
by Technology

Delivering faster, better, cheaper oncology trial results for biotech sponsors

Our Oncology CRO Executive Team

Our Oncology CRO team has extensive experience leading CROs across indications

Our experienced CRO executive team works closely with our expert site operations team to continuously review execution strategies, closely monitor patient recruitment efforts, and mitigate key study risks for oncology clinical trials.

large-Rich McCormick

Richard McCormick Jr.

EVP of Clinical Strategy

Prominent leader, clinical operations and project management professional with 20+ years of experience specializing in hematology and oncology indications to support complex oncology research for biotech clients.

Powered By Our Connected Technology Platform

The Vial Technology Platform leverages connected systems and intuitive design to run global trials efficiently at scale

Vial’s modern technology platform brings clinical trials out of the paper stone age, allowing for streamlined processes inside one end-to-end system.

NGS Integrations

Integrations with leading NGS providers and multi-omics vendors to support targeted oncology sponsors.

No-Nonsense Pricing

Vial offers sponsors fixed-pricing
agreements with no change orders — ever.

Flat-rate pricing

Zero change orders

Risk-share
on commitments

Accountability
on commitments

A fixed-fee pricing model guarantees a set budget for the entirety of a project, regardless of the time and expense that accrues. Vial reserves the right to modify pricing in accordance with amendments to the study design or protocol.

Vial offers fixed upfront pricing to benefit sponsors:

  • Align Incentives
  • Transparent budget visibility
  • No unexpected charges/fees
  • Shared accountability on commitments
  • Build trust and deepen the relationship
  • Experienced team committed to timelines
  • Next-generation technology to streamline workflows and process
  • A renowned scientific advisory board providing expert insight
  • Deep industry relationships and a preferred site network provide an insider view on trial pain points, allowing us to target and prepare to prevent common errors or delays

Modern Recruiting Platform

We recruit patients across multiple channels and convert them to randomizations — radically reducing enrollment periods

vial
vial

We use the most effective digital tools to reach, screen, and enroll motivated subjects quicker. Our optimized process can cut recruitment times in half.

EMR Integrations

HIPAA compliant automated data pulls and Inclusion/Exclusion reviews.

Fast Start-up and Consolidated Site Activation

Vial’s Site Startup App enables sites to seamlessly onboard to our trials

The results: Lightning fast onboarding for sites to be activated in as few as 30 days.

Scientific Advisory Board

Vial CRO is supported by a team of Scientific Advisors who review and provide input on the strategy and direction of the CRO in order to build the infrastructure to advance Oncology research.

Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School View Profile
Professor of Medicine and Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah View Profile
CEO at Urology Cancer Center and XCancer Research View Profile
Director of Summit Cancer Centers, Medical Oncologist View Profile
Head of Clinical Development at PACT Pharma View Profile
Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA) View Profile

Medical Director for Lean and Quality Improvement, Chair of the Lymphoma/Myeloma Disease Working Group, and Associate Professor at the University of Kansas

View Profile

Professor of Medicine and the Director of the Lung Cancer Medical Oncology Program at the Cleveland Clinic Taussig Cancer Institute

View Profile

Clinical Executive Director at AccessHope, thoracic oncology specialist and Associate Clinical Professor in Medical Oncology at City of Hope Cancer Center

View Profile

Genitourinary Medical Oncology Professor and Physician, The University of Texas MD Anderson Cancer Center

View Profile

Chief of Clinical Trials at Vanderbilt University

View Profile

Experience across
Immuno-Oncology

Monoclonal Antibodies

Cell Therapy - Adoptive Cell Therapies & Car T Cell:

Checkpoint Inhibitors

Cancer Vaccines

The Vial Oncology CRO is supported by a team of scientific advisors with expertise across therapies in immuno-oncology. These advisors provide input on the strategy and direction of the CRO in order to build the infrastructure to advance the research of monoclonal antibodies.

Dr. Neeraj Agarwal

Read More

Professor of Medicine and Presidential Endowed Chair of Cancer Research
at the Huntsman Cancer Institute, University of Utah

Dr. Guru Sonpavde

Read More

Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard
Medical School

The Vial Oncology CRO is supported by a team of scientific advisors with expertise across therapies in immuno-oncology. These advisors provide input on the strategy and direction of the CRO in order to build the infrastructure to advance the research of cell therapies.

Dr. Arati Rao

Read More

Head of Clinical Development at PACT Pharma

The Vial Oncology CRO is supported by a team of scientific advisors with expertise across therapies in immuno-oncology. These advisors provide input on the strategy and direction of the CRO in order to build the infrastructure to advance the research of checkpoint inhibitors.

Dr. Antoni Ribas

Read More

Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA)

Dr. Guru Sonpavde

Read More

Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard
Medical School

Dr. Nathan Pennell

Read More

Professor of Medicine and the Director of the Lung Cancer Medical Oncology Program at the Cleveland Clinic Taussig Cancer Institute

Dr. Brian Rini

Read More

Chief of Clinical Trials and Professor of Medicine at Vanderbilt University

The Vial Oncology CRO is supported by a team of scientific advisors with expertise across therapies in immuno-oncology. These advisors provide input on the strategy and direction of the CRO in order to build the infrastructure to advance the research of cancer vaccines.

Dr. Guru Sonpavde

Read More

Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard
Medical School

Dr. Eric Jonasch

Read More

Genitourinary Medical Oncology Professor and Physician at The University of Texas MD Anderson Cancer Center

White Paper

Tech-Enabled Remote Monitoring Part 1

Download the Vial CRO's white paper to learn more about each stakeholder’s benefits of tech-enabled trials.

White Paper

Tech-Enabled Remote Monitoring Part 2

Download the Vial CRO's white paper to learn more about each stakeholder’s benefits of tech-enabled trials.

White Paper

Vial’s Deployment of Modern, Intuitive Electronic Source

Download the Vial CRO's latest white paper to learn how utilizing eSource in clinical trials can streamline process, increase efficiency, and minimize...

Articles

Understanding Tumor Variability and Defining the 5 Stages of Cancer

Articles

How to Manage a Kidney Cancer Clinical Trial

Articles

First FDA-Approved Adenoviral Vector-Based Gene Therapy for Bladder Cancer

oncology cro

Advancing Cancer Care

Despite significant progress in cancer research, many patients still face limited treatment options.

Clinical trials are essential for developing new cancer treatments and advancing care for patients. Vial offers oncology sponsors solutions to support their research, including optimized study design, innovative patient recruitment strategies, and advanced data analytics techniques. By leveraging Vial, sponsors conducting oncology clinical trials can accelerate getting innovative therapies to the market, leading to better patient outcomes and contributing to the global effort to cure cancer.

Indications

Multifaceted Clinical Trial Execution Across Oncology Indications and Phases

Talk to Sales

Interested in receiving a proposal from Vial? Leave us a message and some of your contact info and we’ll be in touch with you shortly.